RECEIVED
CENTRAL FAX CENTER
SEP 12 2007

Amendments to the claims:

This listing of claims will replace all prior versions and listings of claims in the present application:

Listing of claims

Claim 1. (Original) A multi-dosage liquid pharmaceutical formulation of human growth hormone consisting essentially of human growth hormone at a concentration of from about 5 mg/ml to about 100 mg/ml, glycine, a buffer, a non-ionic surfactant, and a preservative, said pharmaceutical formulation having a tonicity of from about 100 to about 500 mosm/kg and having a pH from about 6.1 to about 6.3.

Claim 2. (Original) The pharmaceutical formulation according to claim 1, wherein the concentration of human growth hormone is from about 6 mg/ml to 14 mg/ml.

Claim 3. (Original) The pharmaceutical formulation according to claim 2, wherein the concentration of human growth hormone is about 6.67 mg/ml.

Claim 4. (Original) The pharmaceutical formulation according to claim 1, wherein the concentration of glycine is from about 5 mg/ml to about 75 mg/ml.

Claim 5. (Original) The pharmaceutical formulation according to claim 1, wherein the concentration of glycine is about 15 mg/ml.

Claim 6. (Original) The pharmaceutical formulation according to claim 1, said pharmaceutical composition being substantially isotonic.

Claim 7. (Original) The pharmaceutical formulation according to claim 1, wherein the buffer is selected from the group consisting of a phosphate buffer, a citrate buffer, an acetate buffer and a formate buffer.

Claim 8. (amended) The pharmaceutical formulation according to claim 7, wherein the buffer is a phosphate buffer.

Claim 9. (Original) The pharmaceutical formulation according to claim 1, wherein the buffer has a concentration of from about 5 mM to about 100 mM.

Claim 10. (Original) The pharmaceutical formulation according to claim 1, wherein the buffer has a concentration of about 10 mM.

Claim 11. (canceled)

Claim 12. (Original) The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is selected from the group consisting of a poloxamer and a polysorbate.

PAGE 3/8 * RCVD AT 9/12/2007 3:56:10 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-2/21 * DNIS:2738300 * CSID:16096278636 * DURATION (mm-ss):04-02

Claim 13. (canceled)

Claim 14. (Original) The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is poloxamer 188.

Claim 15. (Original) The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is present at a concentration of from about 0.05 to about 4 mg/ml.

Claim 16. (canceled)

Claim 17. (canceled)

Claim 18. (Original) The pharmaceutical formulation according to claim 1, wherein the preservative is selected from the group consisting of benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, phenol, benzalkonium chloride, benzethonium chloride, chlorobutanol, 2-phenoxyethanol, phenyl mercuric nitrate and thimerosal.

Claim 19. (Original) The pharmaceutical formulation according to claim 1, wherein the preservative is benzyl alcohol.

Claim 20. (Original) The pharmaceutical formulation according to claim 1, wherein the preservative is benzyl alcohol being present at a concentration of from about 7 mg/ml to about 12 mg/ml.

Claim 21. (Original) The pharmaceutical formulation according to claim 1, said pharmaceutical composition having a pH of about 6.2.

Claim 22. (Currently amended) The pharmaceutical composition according to claim 1, ~~essentially~~ consisting essentially of 6.67 mg/ml human growth hormone,
15 mg/ml ~~propylene~~ glycine,
10 mM sodium phosphate buffer,
2 mg/ml poloxamer 188,
9 mg/ml benzyl alcohol,

and having a pH of 6.2.

Claim 23. (Original) A kit comprising an injection device and a separate container containing a multi-dosage liquid formulation of human growth hormone according to claim 1.

PAGE 4/8 * RCVD AT 9/12/2007 3:56:10 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-2/21 * DNIS:2738300 * CSID:16096278636 * DURATION (mm-ss):04-02